Dianthus Therapeutics (DNTH) Common Equity (2017 - 2025)

Dianthus Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $493.4 million for Q4 2025.

• On a quarterly basis, Common Equity rose 39.98% year-over-year to $493.4 million in Q4 2025; TTM through Dec 2025 was $493.4 million, a 39.98% increase from a year earlier, with the FY2025 full-year figure at $493.4 million, up 39.98% from the prior year.
• Common Equity retreated to $493.4 million in Q4 2025 per DNTH's latest filing, from $546.5 million in the prior quarter.
• Across five years, Common Equity topped out at $546.5 million in Q3 2025 and bottomed at -$61.5 million in Q2 2023.
• The 5-year median for Common Equity is $184.0 million (2021), against an average of $185.2 million.
• Across the five-year window, Common Equity slumped 157.22% in 2022 and jumped 833.35% in 2024, its largest moves.
• Year by year, Common Equity stood at -$17.2 million in 2021, then tumbled by 157.22% to -$44.4 million in 2022, then soared by 480.61% to $168.9 million in 2023, then surged by 108.73% to $352.5 million in 2024, then surged by 39.98% to $493.4 million in 2025.
• Per Business Quant, the three latest DNTH Common Equity figures stand at $493.4 million (Q4 2025), $546.5 million (Q3 2025), and $303.1 million (Q2 2025).